Marsico Capital Management LLC Takes $5.40 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Marsico Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 173,075 shares of the company’s stock, valued at approximately $5,402,000.

Several other hedge funds and other institutional investors also recently modified their holdings of TEVA. AQR Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after acquiring an additional 4,732 shares during the period. Focus Partners Wealth boosted its holdings in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares during the period. Franklin Resources Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $255,000. Flow Traders U.S. LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter worth about $238,000. Finally, Cerity Partners LLC lifted its holdings in Teva Pharmaceutical Industries by 2.9% in the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after purchasing an additional 1,291 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $34.55 on Friday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $39.73 billion, a price-to-earnings ratio of 25.98, a PEG ratio of 3.43 and a beta of 0.84. The firm has a 50-day moving average of $33.19 and a two-hundred day moving average of $31.95.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on TEVA. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the sale, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.